SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines

Frontiers in Cellular and Infection Microbiology

Desh Deepak Singh¹  Dharmendra Kumar Yadav²  Amna Parveen² 

[1] Amity Institute of Biotechnology, Amity University Rajasthan, Jaipur, India;Gachon Institute of Pharmaceutical Science and Department of Pharmacy, College of Pharmacy, Gachon University, Incheon, South Korea;

关键词: SARS-CoV-2;    variant;    vaccine;    neutralization;    infectivity;   

DOI  :  10.3389/fcimb.2021.777212

来源: Frontiers

【 摘 要 】

The emergence of SARS-CoV-2 variants may cause resistance at the immunity level against current vaccines. Some emergent new variants have increased transmissibility, infectivity, hospitalization, and mortality. Since the administration of the first SARS-CoV-2 vaccine to a human in March 2020, there is an ongoing global race against SARS-CoV-2 to control the current pandemic situation. Spike (S) glycoprotein of SARS-CoV-2 is the main target for current vaccine development, which can neutralize the infection. Companies and academic institutions have developed vaccines based on the S glycoprotein, as well as its antigenic domains and epitopes, which have been proven effective in generating neutralizing antibodies. The effectiveness of SARS-CoV-2 vaccines and other therapeutics developments are limited by the new emergent variants at the global level. We have discussed the emergent variants of SARS-CoV-2 on the efficacy of developed vaccines. Presently, most of the vaccines have been tremendously effective in severe diseases. However, there are still noteworthy challenges in certifying impartial vaccines; the stories of re-infections are generating more stressful conditions, and this needs further clinical evaluation.

【 授权许可】

CC BY